Adaptations of nanoscale viruses and other protein cages for medical applications

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 2, Issue 3, 2006, Pages 137-149

  Lee, L Andrew ^a   Wang, Qian ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bionanoparticles; Protein assemblies; Protein cages; Viral nanoparticles; Virus based therapeutics

Indexed keywords

BIONANOPARTICLES; PROTEIN ASSEMBLIES; PROTEIN CAGES; VIRAL NANOPARTICLES; VIRUS-BASED THERAPEUTICS;

CONTROLLED DRUG DELIVERY; COPOLYMERS; DENDRIMERS; MEDICAL APPLICATIONS; MEDICAL IMAGING; NANOSTRUCTURED MATERIALS; PROTEINS;

VIRUSES;

CYSTEINE; DOXORUBICIN; DRUG CARRIER; FERRITIN; FLUORESCENT DYE; GLUTAMIC ACID; HEPATITIS B VIRUS PROTEIN; HYDRAZONE DERIVATIVE; MEMBRANE COFACTOR PROTEIN; METHOTREXATE; NANOPARTICLE; POLYOMA VIRUS LIKE PROTEIN; PROTEIN; TOBACCO MOSAIC VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; WART VIRUS VACCINE;

ADAPTATION; BINDING AFFINITY; BUILDING MATERIAL; CANCER PATIENT; CLINICAL TRIAL; DRUG RELEASE; ENCAPSULATION; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENITAL SYSTEM DISEASE; GENITAL TRACT INFECTION; HEPATITIS B VIRUS; HUMAN; IMAGING SYSTEM; IMMUNIZATION; IMMUNOMODULATION; JC VIRUS; NANOTECHNOLOGY; NANOVIRUS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PAPILLOMA VIRUS; PLANT VIRUS; POLYOMA VIRUS; PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TARGET CELL; TOBACCO MOSAIC VIRUS; TURNIP YELLOW MOSAIC VIRUS; VACCINE PRODUCTION; VACCINIA VIRUS; VERRUCA VULGARIS; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS RECOMBINANT; WART VIRUS;

BIOMIMETIC MATERIALS; CONTRAST MEDIA; DRUG CARRIERS; NANOSTRUCTURES; PHARMACEUTICAL PREPARATIONS; PROTEINS; VACCINES; VIRION;

PAPILLOMAVIRIDAE; VACCINIA VIRUS;

EID: 33748741173     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2006.07.009     Document Type: Review

References (116)

1. Niemeyer C.M. Nanoparticles, protein, and nucleic acids: Biotechnology meets materials science. Angew Chem Int Ed 40 (2001) 4128-4158
2. Dujardin E., and Mann S. Bio-inspired materials chemistry. Adv Eng Mater 4 (2002) 461-474
3. Seeman N.C. At the crossroads of chemistry, biology, and materials: Structural DNA nanotechnology. Chem Biol 10 (2003) 1151-1159
4. Shih W.M., Quispe J.D., and Joyce G.F. A 1.7-kilobase single-stranded DNA that folds into a nanoscale octahedron. Nature. 427 (2004) 618-621
5. Georgens C., Weyermann J., and Zimmer A. Recombinant virus like particles as drug delivery system. Curr Pharm Biotechnol 6 (2005) 49-55
6. Muller O.J., et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 21 (2003) 1040-1046
7. Peng K.W., et al. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor. Gene Ther 11 (2004) 1234-1239
8. May T., Gleiter S., and Lilie H. Assessment of cell type specific gene transfer of polyoma virus like particles presenting a tumor specific antibody Fv fragment. J Virol Methods 105 (2002) 147-157
9. Kramer R.M., et al. Engineered protein cages for nanomaterial synthesis. J Am Chem Soc 126 (2004) 13282-13286
10. Ensign D., Young M., and Douglas T. Photocatalytic synthesis of copper colloids from Cu(II) by the ferrihydrite core of ferritin. Inorg Chem 43 (2004) 3441-3446
11. Hosein H.A., et al. Iron and cobalt oxide and metallic nanoparticles prepared from ferritin. Langmuir 20 (2004) 10283-10287
12. Flenniken M.L., et al. The small heat shock protein cage from Methanococcus jannaschii is a versatile nanoscale platform for genetic and chemical modification. Nano Lett 3 (2003) 1573-1576
13. Flenniken M.L., et al. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem Commun (Camb) (2005) 447-449
14. Flenniken M.L., et al. Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture. Chem Biol 13 (2006) 161-170
15. Raja K.S., and Wang Q. Bionanoparticles and Nanotechnology. In: Schwarz J.A., Contescu C.I., and Putyera K. (Eds). Encyclopedia of Nanoscience and Nanotechnology, Vol. B (2004), Marcel Dekker, New York 321-330
16. Seebeck F.P., et al. A simple tagging system for protein encapsulation. J Am Chem Soc 128 (2006) 4516-4517
17. Rai P., et al. Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins. Nat Biotechnol 24 (2006) 582-586
18. Hodge J.W., et al. Enhanced activation of T-cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst 92 (2000) 1228-1239
19. Hodge J.W., et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 59 (1999) 5800-5807
20. Bachmann M.F., et al. The influence of antigen organization on B-cell responsiveness. Science 262 (1993) 1448-1451
21. Bachmann M.F., Zinkernagel R.M., and Oxenius A. Immune responses in the absence of costimulation: viruses know the trick. J Immunol 161 (1998) 5791-5794
22. Wong K.K.W., et al. Biomimetic synthesis and characterization of magnetic proteins (magnetoferritin). Chem Mater 10 (1998) 279-285
23. Douglas T., and Stark V.T. Nanophase cobalt oxyhydroxide mineral synthesized within the protein cage of ferritin. Inorg Chem 39 (2000) 1828-1830
24. Paavola C., et al. A versatile platform for nanotechnology based on circular permutation of a chaperonin protein. Nanotechnology 17 (2006) 1171-1176
25. Kerfeld C.A., et al. Protein structures forming the shell of primitive bacterial organelles. Science 309 (2005) 936-938
26. Verheije M.H., et al. Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter. J Virol 80 (2006) 1250-1260
27. Shin Y.C., and Folk W.R. Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor. J Virol 77 (2003) 11491-11498
28. Gleiter S., and Lilie H. Cell-type specific targeting and gene expression using a variant of polyoma VP1 virus-like particles. Biol Chem 384 (2003) 247-255
29. Lomonossoff G.P., and Johnson J.E. Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines. Curr Opin Struct Biol 6 (1996) 176-182
30. Lomonossoff G.P., and Hamilton W.D.O. Cowpea mosaic virus-based vaccines. Curr Top Microbiol Immunol 240 (1999) 177-189
31. Arvin A.M., and Greenberg H.B. New viral vaccines. Virology 344 (2006) 240-249
32. Navarro J., et al. Gene delivery systems: bridging the gap between recombinant viruses and artificial vectors. Adv Drug Deliv Rev 30 (1998) 5-11
33. Young L.S., et al. Viral gene therapy strategies: from basic science to clinical application. J Pathol 208 (2006) 299-318
34. Wang Q., et al. Blue fluorescent antibodies as reporters of steric accessibility in virus conjugates. Bioconjug Chem 14 (2003) 38-43
35. Wang Q., et al. Icosahedral virus particles as addressable nanoscale building blocks. Angew Chem Int Ed Engl 41 (2002) 459-462
36. Wang Q., et al. Natural supramolecular building blocks: cysteine-added mutants of cowpea mosaic virus. Chem Biol 9 (2002) 813-819
37. Wang Q., et al. Natural supramolecular building blocks: wild-type cowpea mosaic virus. Chem Biol 9 (2002) 805-811
38. Raja K.S., et al. Hybrid virus-polymer materials. 1. Synthesis and Properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 4 (2003) 472-476
39. Strable E., Johnson J.E., and Finn M.G. Natural nanochemical building blocks: icosahedral virus particles organized by attached oligonucleotides. Nano Lett 4 (2004) 1385-1389
40. Chatterji A., et al. Cowpea mosaic virus: from the presentation of antigenic peptides to the display of active biomaterials. Intervirology 45 (2002) 362-370
41. Raja K.S., Wang Q., and Finn M.G. Icosahedral virus particles as polyvalent carbohydrate display platforms. Chembiochem 4 (2003) 1348-1351
42. Sen Gupta S., et al. Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconjug Chem 16 (2005) 1572-1579
43. Gillitzer E., et al. Chemical modification of a viral cage for multivalent presentation. Chem Commun (Camb) (2002) 2390-2391
44. Taylor D., et al. Correlation of chemical reactivity of Nudaurelia capensis omega virus with a pH-induced conformational change. Chem Commun (Camb) (2003) 2770-2771
45. Schlick T.L., et al. Dual-surface modification of the tobacco mosaic virus. J Am Chem Soc 127 (2005) 3718-3723
46. Barnhill H.N., et al. Dual modification of turnip yellow mosaic virus: synthesis of a biotinylated luminescent nanoparticle. Proceedings of the 231st American Chemical Society National Meeting, Atlanta, GA, March 26-30, 2006. Polymer and material science engineering (PMSE) (2006)
47. Soto C.M., et al. Fluorescent signal amplification of carbocyanine dyes using engineered viral nanoparticles. J Amer Chem Soc 128 (2006) 5184-5189
48. Hooker J.M., Kovacs E.W., and Francis M.B. Interior surface modification of bacteriophage MS2. J Am Chem Soc 126 (2004) 3718-3719
49. Peabody D.S. A viral platform for chemical modification and multivalent display. J Nano Bio Tech 1 (2003) 5
50. Mammen M., Choi S.-K., and Whitesides G.M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed Engl 37 (1998) 2754-2794
51. Discher D.E., Janmey P., and Wang Y.L. Tissue cells feel and respond to the stiffness of their substrate. Science 310 (2005) 1139-1143
52. Jeong K.J., Mabry R., and Georgiou G. Avimers hold their own. Nat Biotechnol 23 (2005) 1493-1494
53. Silverman J., et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23 (2005) 1556-1561
54. Khor I.W., et al. Novel strategy for inhibiting viral entry by use of a cellular receptor-plant virus chimera. J Virol 76 (2002) 4412-4419
55. Manchester M., et al. Measles virus recognizes its receptor, CD46, via two distinct binding domains within Scr1-2. Virology 233 (1997) 174-184
56. Manchester M., et al. Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus. Proc Natl Acad Sci U S A 91 (1994) 2161-2165
57. Oh I.K., Mok H., and Park T.G. Folate immobilized and pegylated adenovirus for retargeting to tumor cells. Bioconjug Chem 17 (2006) 721-727
58. Lewis J.D., et al. Viral nanoparticles as tools for intravital vascular imaging. Nat Med 12 (2006) 354-360
59. Weissleder R., et al. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 23 (2005) 1418-1423
60. Smith A.E., Lilie H., and Helenius A. Ganglioside-dependent cell attachment and endocytosis of murine polyomavirus-like particles. FEBS Lett 555 (2003) 199-203
61. Sandalon Z., and Oppenheim A. Self-assembly and protein-protein interactions between the SV40 capsid proteins produced in insect cells. Virology 237 (1997) 414-421
62. Chang D., et al. Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J Gen Virol 78 (1997) 1435-1439
63. Gillock E.T., et al. Polyomavirus major capsid protein VP1 is capable of packaging cellular DNA when expressed in the baculovirus system. J. Virol 71 (1997) 2857-2865
64. Sasnauskas K., et al. Yeast cells allow high-level expression and formation of polyomavirus-like particles. Biol Chem 380 (1999) 381-386
65. Schmidt U., et al. Site-specific fluorescence labeling of recombinant polyomavirus-like particles. Biol Chem 380 (1999) 397-401
66. Ou W.C., et al. The major capsid protein, VP1, of human JC virus expressed in Escherichia coli is able to self-assemble into a capsid-like particle and deliver exogenous DNA into human kidney cells. J Gen Virol 80 (1999) 39-46
67. Tsai B., et al. Gangliosides are receptors for murine polyoma virus and SV40. EMBO J 22 (2003) 4346-4355
68. Caruso M., et al. α4β1 Integrin acts as a cell receptor for murine polyomavirus at the postattachment level. J Virol 77 (2003) 3913-3921
69. Caruso M., et al. Role of sialic acid-containing molecules and the (4(1 integrin receptor in the early steps of polyomavirus infection. J Gen Virol 84 (2003) 2927-2936
70. Sabath B.F., and Major E.O. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 186 (2002) S180-S186
71. Wang M., et al. Inhibition of simian virus 40 large tumor antigen expression in human fetal glial cells by an antisense oligodeoxynucleotide delivered by the JC virus-like particle. Hum Gene Ther 15 (2004) 1077-1090
72. Yamada T., et al. Novel tissue and cell type-specific gene/drug delivery system using surface engineered hepatitis B virus nano-particles. Curr Drug Targets Infect Disord 4 (2004) 163-167
73. Yu D., et al. The specific delivery of proteins to human liver cells by engineered bio-nanocapsules. FEBS J 272 (2005) 3651-3660
74. Yamada T., et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol 21 (2003) 885-890
75. Gleiter S., and Lilie H. Coupling of antibodies via protein Z on modified polyomavirus-like particles. Protein Sci 10 (2001) 434-444
76. Chatterji A., et al. New addresses on an addressable virus nanoblock; uniquely reactive Lys residues on cowpea mosaic virus. Chem Biol 11 (2004) 855-863
77. Chatterji A., et al. Chemical conjugation of heterologous proteins on the surface of cowpea mosaic virus. Bioconjug Chem 15 (2004) 807-813
78. Wang Q., et al. Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J Am Chem Soc 125 (2003) 3192-3193
79. Zhan W.H., et al. Synthesis of hemicyanine dyes for "click" bioconjugation. Tetrahedron Lett 46 (2005) 1691-1695
80. Krauzewicz N., et al. Sustained ex vivo and in vivo transfer of a reporter gene using polyomavirus pseudocapsids. Gene Ther 7 (2000) 1094-1102
81. Touze A., et al. Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells. J Gen Virol 82 (2001) 3005-3009
82. Osterman J.V., Waddell A., and Aposhian H.V. DNA and gene therapy: uncoating of polyoma pseudovirus in mouse embryo cells. Proc Natl Acad Sci U S A. 67 (1970) 37-40
83. Kimchi-Sarfaty C., and Gottesman M.M. SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy. Curr Pharm Biotechnol 5 (2004) 451-458
84. Kimchi-Sarfaty C., et al. In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer. Hum Gene Ther 13 (2002) 299-310
85. Kimchi-Sarfaty C., et al. High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences. Hum Gene Ther 14 (2003) 167-177
86. Krauzewicz N., et al. Virus-like gene transfer into cells mediated by polyomavirus pseudocapsids. Gene Ther 7 (2000) 2122-2131
87. Kimchi-Sarfaty C., et al. Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions. Hum Gene Ther 16 (2005) 1110-1115
88. Rae C.S., et al. Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology 343 (2005) 224-235
89. Ewers H., et al. Single-particle tracking of murine polyoma virus-like particles on live cells and artificial membranes. Proc Natl Acad Sci U S A 102 (2005) 15110-15115
90. Wu C., et al. A new probe using hybrid virus-dye nanoparticles for near-infrared fluorescence tomography. Opt Commun 255 (2005) 366-374
91. Medintz I.L., et al. Decoration of discretely immobilized cowpea mosaic virus with luminescent quantum dots. Langmuir 21 (2005) 5501-5510
92. Chatterji A., et al. A virus-based nanoblock with tunable electrostatic properties. Nano Lett 5 (2005) 597-602
93. Portney N.G., et al. Organic and inorganic nanoparticle hybrids. Langmuir 21 (2005) 2098-2103
94. Blum A.S., et al. An engineered virus as a scaffold for three-dimensional self-assembly on the nanoscale. Small. 1 (2005) 702-706
95. Souza G.R., et al. Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents. Proc Natl Acad Sci U S A 103 (2006) 1215-1220
96. Schmidt U., et al. Protein and peptide delivery via engineered polyomavirus-like particles. FASEB J 15 (2001) 1646-1648
97. Abbing A., et al. Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem 279 (2004) 27410-27421
98. Johnson J., Lin T., and Lomonossoff G. Presentation of heterologous peptides on plant viruses: genetics, structure, and function. Annu Rev Phytopathol 35 (1997) 67-86
99. Dalsgaard K., et al. Plant-derived vaccine protects target animals against a viral disease. Nat Biotechnol 15 (1997) 248-252
100. Langeveld J.P., et al. Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus. Vaccine 19 (2001) 3661-3670
101. Marusic C., et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J Virol 75 (2001) 8434-8439
102. Yusibov V., et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20 (2002) 3155-3164
103. Koo M., et al. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci U S A 96 (1999) 7774-7779
104. Smith M.L., et al. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology 348 (2006) 475-488
105. Brennan F.R., et al. A chimaeric plant virus vaccine protects mice against a bacterial infection. Microbiology 145 (1999) 2061-2067
106. Brennan F.R., et al. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus. Microbiology 145 (1999) 211-220
107. Rennermalm A., et al. Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. Vaccine 19 (2001) 3376-3383
108. Villa L.L., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
109. Villa L.L., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24 (2006) 5571-5583
110. Chen X.S., et al. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5 (2000) 557-567
111. Harding J.A., et al. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta 1327 (1997) 181-192
112. Xu Z.L., et al. Approaches to improving the kinetics of adenovirus-delivered genes and gene products. Adv Drug Deliv Rev 57 (2005) 781-802
113. Croyle M.A., et al. Pegylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 13 (2002) 1887-1900
114. Singh P., Gonzalez M.J., and Manchester M. Viruses and their uses in nanotechnology. Drug Dev Res 67 (2006) 23-41
115. Dirksen A., et al. A supramolecular approach to multivalent target-specific MRI contrast agents for angiogenesis. Chem Commun (Camb) (2005) 2811-2813
116. Kobayashi H., and Brechbiel M.W. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev 57 (2005) 2271-2286